Insmed Incorporated — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. The filing also reports unaudited quarterly results, including fourth-quarter 2012. Insmed is a clinical-stage biopharmaceutical company focused primarily on ARIKACE, an inhaled liposomal amikacin candidate for serious lung infections.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $0 | $4.4 million |
| Research and development expense | $29.8 million | $28.6 million |
| General and administrative expense | $12.7 million | $11.5 million |
| Operating loss | $42.4 million | $61.7 million |
| Net loss attributable to common stockholders | $41.4 million ($1.56 per share) | $68.8 million ($2.95 per share) |
| Net cash used in operating activities | $31.0 million | $30.2 million |
| Cash, cash equivalents and certificate of deposit at year-end | $92.9 million | $78.4 million |
| Total assets | $153.6 million | $139.8 million |
| Total debt, net of issuance discounts and current portion | $19.2 million | $0 |
| Stockholders’ equity | $120.9 million | $134.3 million |
Insmed had no product revenue and reported no revenue in 2012. FY2011 revenue included $3.4 million from the IPLEX expanded-access program and $1.0 million in licensing fees. Profit margins are not meaningful given the absence of revenue and ongoing development costs.
FY2012 net loss improved from FY2011, chiefly because FY2011 included a $26.0 million non-cash impairment charge and a $9.2 million non-cash beneficial-conversion charge. FY2012 included approximately $2.9 million of severance costs. R&D expense rose 4%; clinical manufacturing costs increased as more ARIKACE lots were produced. Investment income declined to $1.8 million from $2.1 million, while interest expense rose to $0.8 million following new borrowing.
Fourth-quarter 2012 revenue was $0; operating loss was $15.8 million and net loss was $15.5 million, versus a $9.4 million net loss in the third quarter. Full-year operating cash use was $31.0 million. Investing cash inflow of $61.5 million primarily reflected net sales of short-term investments; financing provided $45.4 million, including $20.0 million of debt and $25.7 million from common-stock issuance. Management said available funds were sufficient for 2013, while warning that additional capital may be needed.
Business, development and outlook
ARIKACE was in a Phase 3 trial in Europe and Canada for cystic-fibrosis patients with Pseudomonas lung infections; enrollment of 302 patients was completed in November 2012. Results were expected in mid-2013. A Phase 2 study for non-tuberculous mycobacteria (NTM) infections began enrolling in June 2012, with results expected in the fourth quarter of 2013. The company also planned a limited NTM compassionate-use program in the second half of 2013. A Phase 2 study for non-CF bronchiectasis was complete, but further development was deferred pending results in the lead indications.
Management’s priorities included completing trials, pursuing regulatory filings, scaling manufacturing and preparing for potential commercialization in Europe and Canada, with US plans for CF to be reconsidered after Phase 3 results. Insmed planned to begin building commercial capabilities and to hire additional personnel. These are plans, not assurances of approval or launch; no revenue or profitability guidance was provided.
Risks, contingencies and unusual items
- Clinical and regulatory uncertainty: FDA holds on ARIKACE trials were lifted in January and May 2012, but the relevance to humans of lung tumors observed in 2 of 120 high-dose rats in a two-year inhalation study remains unknown. The FDA requested a nine-month dog inhalation toxicity study. The company reported no neoplasia or proliferative changes in the interim review of the first group; the recovery period and final report remained pending.
- Funding and ongoing losses: Accumulated deficit was $335.5 million. Insmed expected continued losses and did not expect significant revenue for several years, if ever. It reported no committed source of future capital.
- Debt and supply concentration: The $20.0 million Hercules loan bears 9.25% interest and is secured by company assets other than intellectual property. ARIKACE and its delivery nebulizer depended on sole suppliers, and commercial supply agreements had not been established.
- Internal controls and equity awards: Management and Ernst & Young identified a material weakness in administration, accounting and oversight of the stock incentive plan; management concluded disclosure controls and internal control over financial reporting were ineffective at year-end. The auditor issued an adverse opinion on internal controls but an unqualified opinion on the financial statements. Excess awards of approximately 1.6 million shares were subject to remediation and shareholder ratification; Nasdaq consequences remained possible.
- Legal matters: A former Transave stockholder appraisal action involving approximately 7.77 million dissenting shares remained pending; the company could not estimate any potential loss. A separate IPLEX-related case was dismissed on summary judgment, but an appeal was filed in March 2013.
- Other material exposures: Potential dilution from stock issuance and awards; reimbursement, pricing, competition, patent and manufacturing risks; and possible impairment of the $58.2 million in-process R&D asset. The company also disclosed that FDA objected to the proposed ARIKACE trade name.
Key facts investors should verify
- Results and regulatory implications of the CF Phase 3 and NTM Phase 2 trials, and whether their timing or design changed.
- Final dog-toxicity study findings and any FDA requirements related to the rat tumor observations.
- Cash runway, future financing needs, and the effects of the 9.25% secured debt and scheduled principal repayments.
- Remediation of the stock-plan control weakness, shareholder action on affected awards, and any Nasdaq decision.
- Manufacturing scale-up and supply agreements for ARIKACE and the nebulizer, plus resolution of the proposed product name.
- Status and potential financial impact of the Transave appraisal litigation and any other contingencies.